Levodopa, placebo and rotigotine change biomarker levels for oxidative stress
Objective: The objective was to investigate the influence of the D1 receptor agonists levodopa and rotigotine compared with placebo on homocysteine and cysteinyl-glycine in plasma…Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease diagnosis
Objective: To evaluate the diagnostic value of combined acute levodopa challenge and olfactory testing to predict PD diagnosis. Background: Acute levodopa challenge can be used…Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?
Objective: The aim of this study was to explore the angiogenetic hypothesis for Levodopa-induced-dyskinesia (LID) using advanced MRI methods in patients with Parkinson's disease (PD).…Dopaminergic and non-dopaminergic effects on instrumented timed up and go test in patients with Parkinson’s disease
Objective: To evaluate an instrumented version of Timed Up and Go Test (iTUG) in patients with Parkinson's disease (PD), both in L-dopa OFF and ON-state.…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Healthcare burden of Parkinson’s disease
Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves
Objective: Idiopathic Parkinson's disease (IPD) is a chronic neurodegenerative disorder. Most of the clinicians believe that it is limited with motor and cognitive disorders. However,…An atypical case of adult-onset, levodopa-responsive, paroxysmal dystonia
Objective: To describe a case of adult-onset, levodopa-responsive, paroxysmal dystonia. Background: Adult-onset dystonia cases account for at least 90% of primary dystonia, however, less than…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.